TRT and Atrial Fibrillation Risk: What the Evidence Says

The relationship between testosterone replacement therapy (TRT) and atrial fibrillation (AFib) risk is an area of active research. The 2023 TRAVERSE trial found a 3.5% incidence of AFib in men on TRT versus 2.4% on placebo over 33 months, a statistically significant difference. For men with existing AFib, TRT requires extreme caution and a thorough cardiac workup before starting.

That finding from the TRAVERSE trial is the most concrete data point we have from a large, randomized study. It enrolled over 5,000 men with symptomatic low testosterone. The absolute risk increase was 1.1%, which is small but real, and it informs our understanding of TRT and atrial fibrillation risk.

This guide walks through what that risk means, how it fits into the broader picture of heart rhythm health, and the practical steps to take if you’re considering testosterone therapy with a history of, or risk factors for, atrial fibrillation. We’ll look at the mechanisms, compare the conflicting evidence, and outline a safety-first approach to evaluation.

Key Takeaways

• The TRAVERSE trial showed a 3.5% AFib rate with TRT vs. 2.4% with placebo, establishing a small but real increased risk.
• AFib risk follows a U-shaped curve relative to testosterone; both deficient and supra-physiological levels are problematic.
• Before starting TRT, a cardiac evaluation including EKG, blood pressure, and assessment of sleep apnea is essential for high-risk individuals.
• Subclinical hyperthyroidism (low TSH with normal thyroid hormones) independently raises AFib risk and must be ruled out first.
• For men with existing, symptomatic AFib, TRT is generally contraindicated unless rhythm is fully controlled and closely monitored.

How Does TRT Influence AFib Risk? The U-Shaped Curve

The story isn’t as simple as “testosterone causes AFib.” Emerging evidence paints a more nuanced picture: your risk is lowest when your levels are in a healthy, mid-range zone. Stray too low or push too high, and the risk climbs from both directions.

Some research suggests a complex relationship between testosterone levels and cardiovascular risk. It helps explain why some studies find no link, they might be comparing low-T men who improve to mid-range against a placebo group that stays low. The TRAVERSE trial data showed an increase in AF incidence in the TRT group. This suggests that for some men, even a correct physiological dose might nudge the trt and atrial fibrillation risk upward, particularly if underlying cardiac susceptibility exists.

Common mistake: Focusing only on the “high T” side of the risk. Ignoring that untreated, symptomatic low testosterone is itself a potential risk factor for cardiovascular issues, including arrhythmias, creates a blind spot.

The proposed mechanism isn’t just about thickness. Testosterone increases red blood cell production (hematocrit), which can raise blood viscosity. It also has direct effects on cardiac ion channels and the electrical properties of heart muscle, potentially shortening the atrial refractory period, the “recharge” time between beats, which is a known setup for erratic rhythms.

The Conflicting Data: TRAVERSE vs. Older Meta-Analyses

This is where it gets messy, and where looking at one study in isolation fails.

• The TRAVERSE trial (2023): This is the largest randomized placebo-controlled trial on TRT safety. It found a statistically significant higher incidence of AF with TRT (3.5% vs. 2.4%, P=0.02). However, a 2024 meta-analysis by Corona et al. Found a non-significant pooled odds ratio for AF of 1.44 (95% CI 0.46-4.46) across 106 smaller RCTs, indicating disagreement in the evidence.
• The 2024 Meta-Analysis (Corona et al.): This pooled data from 106 smaller RCTs involving over 15,000 men. It found a non-significant pooled odds ratio for AFib of 1.44, with a confidence interval (0.46-4.46) that crossed 1.0, meaning no definitive link could be established.

How do we reconcile this? The review authors suggest TRAVERSE may be an outlier, or it may have detected a real signal that was underpowered in the myriad of smaller, shorter trials. The takeaway is that the overall risk is likely low, but not zero, and it appears more clearly in large, long-term studies.

Essential Pre-TRT Cardiac Screening for AFib Risk

You wouldn’t start a powerful medication without checking your liver and kidneys. Think of your heart’s electrical system the same way before starting TRT. This isn’t about creating fear; it’s about intelligent, informed management.

The goal is to identify silent or subclinical issues that TRT might unmask or accelerate, central to the trt and atrial fibrillation risk. Skipping this is how men with undiagnosed sleep apnea or a slightly enlarged heart end up in the ER with palpitations two months into therapy.

Here is a concrete checklist. Consider this the minimum for any man over 50, or for any man with symptoms like palpitations, shortness of breath, or unexplained fatigue.

1. Comprehensive Metabolic Panel & Complete Blood Count (CBC): This checks baseline kidney and liver function, and most importantly, hematocrit. A high starting hematocrit is a major red flag.
2. Resting 12-Lead Electrocardiogram (EKG): This non-invasive test takes five minutes and can reveal atrial enlargement, prior silent heart attacks, or conduction abnormalities like Wolff-Parkinson-White syndrome that predispose to arrhythmias.
3. Blood Pressure Assessment: Don’t rely on a single clinic reading. Check it at home, morning and evening, for a week. TRT can sometimes increase blood pressure, and hypertension is a prime driver of atrial remodeling.
4. Thyroid Stimulating Hormone (TSH) Test: This is critical and often missed. Subclinical hyperthyroidism, where TSH is low but thyroid hormones are normal, is a potent independent risk factor for AFib. The 2023 ACC/AHA atrial fibrillation guideline and other sources recommend measuring TSH in the evaluation of new-onset AFib.
5. Sleep Apnea Screening: Use a questionnaire like the STOP-BANG. Untreated sleep apnea causes intermittent hypoxia and wild blood pressure swings, dramatically increasing AFib risk. TRT can worsen sleep apnea in some individuals.
6. Echocardiogram (if indicated): Not everyone needs one. But if the EKG is abnormal, you have a heart murmur, or there’s a history of heart disease, an echo to assess heart structure and function is wise.

Bottom line: This isn’t a barrier; it’s a map. It tells you the lay of the land before you build.

The Critical Role of Thyroid Function

Your thyroid gland acts as your body’s master metabolic thermostat. When it runs too hot, even subtly, your heart rhythm can pay the price. The link between overt hyperthyroidism and AFib is well-known, but the silent danger is subclinical hyperthyroidism.

This condition is diagnosed by a low TSH (typically below 0.4 mIU/L) with free T4 and T3 levels still within the normal reference range. You might feel perfectly fine. But your atrial cells are experiencing a constant, low-grade stimulant.

The data here is robust. A review in Thyroid Research and Practice notes AF occurs in 5–15% of hyperthyroid patients, compared to 1–3% in the general population. For subclinical disease, the hyperthyroidism-related AFib epidemiology review highlights significant risk. The Framingham Heart Study found a relative risk of AF of 3.8 for TSH ≤ 0.1 mIU/L and 1.6 for TSH 0.1–0.4 mIU/L compared to people with normal thyroid function.

A TSH level below 0.4 mIU/L, even with normal T4, should pause any TRT decision. Treat the thyroid first, then re-evaluate.

Guidelines are clear: all patients with overt hyperthyroidism should be treated. For subclinical hyperthyroidism, treatment should be considered in patients older than 65 with TSH < 0.4 mIU/L, or in younger patients with TSH < 0.1 mIU/L. This isn’t optional pedantry, correcting this first removes a major, modifiable arrhythmia trigger that could be falsely blamed on TRT later.

If You Already Have Atrial Fibrillation

This is the most complex scenario. The general principle from endocrine reviews is that TRT is contraindicated or requires extreme caution in patients with unstable or symptomatic existing AFib. The fear is that the hormonal and hematological effects of testosterone could increase the burden of episodes or make rhythm control more difficult.

However, medicine deals in shades of gray. The decision depends on the type and control of your AFib.

AFib Status	TRT Consideration	Key Actions & Monitoring
Paroxysmal (Stable, Infrequent)	Proceed with extreme caution.	Must be well-controlled (<1 episode every few months). Intensify rhythm monitoring (e.g., 2-week Holter 2x/year). Maintain hematocrit <52%.
Persistent (Requires Cardioversion)	Generally not advised.	TRT may be considered only after successful long-term rhythm control (e.g., post-ablation) and with cardiology co-management.
Permanent (Rate-Controlled)	Highest risk. Usually contraindicated.	Focus on optimizing rate control, anticoagulation, and heart failure management. TRT likely introduces more risk than benefit.

Anticoagulation is an important part of management for many patients with AF. The CHA2DS2-VASc score is used to assess stroke risk; NICE guidelines recommend offering anticoagulation to people with AF and a CHA2DS2-VASc score of 2 or above. TRT does not change this calculus, but it makes diligent monitoring of your chosen blood thinner (like checking INR for warfarin) even more important.

Furthermore, if you have AFib and a high hematocrit on TRT, the combination of thicker blood and erratic atrial flow is a perfect storm for clot formation. Donor-directed blood draws (therapeutic phlebotomy) may become a necessary routine.

How Other Supplements and Lifestyle Factors Interact

Testosterone therapy doesn’t exist in a vacuum. What you take and how you live can amplify or mitigate your AFib risk profile. Two major supplement categories require a hard look.

Omega-3 Fatty Acids: This is a classic case of dose and context defining the effect.

• High-Dose Risk: A 2024 meta-analysis of 35 RCTs concluded that high-dose omega-3 (>1500 mg/day) in patients with existing heart disease or high triglycerides increased AFib risk (Odds Ratio 1.43).
• Lower-Dose Data: Conversely, the large JAMA omega-3 and AFib trial (the VITAL Rhythm Trial) found no significant increase in AFib with 840 mg/day in a general prevention population. > Where this goes sideways: Stacking a high-dose fish oil with TRT, especially if you have underlying heart disease, without knowing this interaction. It’s additive risk.

Thyroid Supplements: Iodine, kelp, or thyroid glandular supplements can inadvertently suppress TSH. If you’re self-supplementing for energy, get your TSH checked. You might be quietly pushing yourself into that subclinical hyperthyroidism danger zone.

On the lifestyle front, three factors are non-negotiable:

1. Alcohol: Binge drinking is a famous trigger for “Holiday Heart Syndrome”, acute AFib. Chronic heavy use is a direct toxin to atrial muscle. Moderation is key.
2. Sleep: Treat sleep apnea. Full stop. The evidence linking it to AFib is overwhelming, and CPAP therapy is protective.
3. Exercise: Regular, moderate exercise is protective. Sudden, extreme endurance efforts (like marathon training) can transiently increase risk in susceptible individuals. Build fitness gradually.

These factors matter because they change the baseline your TRT is being added to. A stable, healthy baseline tolerates interventions better than a stressed, inflamed one.

Monitoring and Management: What Does Follow-Up Look Like?

Starting TRT isn’t a “set it and forget it” proposition, especially with arrhythmia risk on the table. A proactive monitoring protocol is your safety net.

First 3-6 Months (The Adjustment Period):

• Hematocrit: Check at 3 months, then every 6-12 months. The goal is to keep it under 52-54%. A rapid rise warrants a dose adjustment or phlebotomy.
• Blood Pressure: Home monitoring weekly. Report any sustained increase >10 mmHg to your doctor.
• Symptoms: Keep a simple log. Note any palpitations, shortness of breath, or lightheadedness. When did they happen? How long did they last?

Ongoing Annual Monitoring:

• Repeat EKG: A yearly EKG can catch slow, progressive changes like atrial enlargement.
• Extended Rhythm Monitoring: This is for higher-risk individuals. If you have occasional skipped beats or rare palpitations, a 2-week event monitor or a 30-day patch monitor once a year can catch paroxysmal AFib that a routine EKG would miss. Studies like EMBRACE and CRYSTAL-AF have proven these methods detect far more AFib than standard follow-up.

When to Sound the Alarm:

Contact your doctor immediately if you experience:

• Heart palpitations that feel rapid, irregular, and sustained (lasting more than 30 minutes).
• Chest pain, pressure, or severe shortness of breath.
• Feeling faint or actually fainting.

This protocol is the standard of care for responsible management. It turns unknown risk into managed variables.

Frequently Asked Questions

Can I take TRT if I already have AFib?

It depends heavily on the type and control of your AFib. For stable, infrequent paroxysmal AFib that is well-managed, TRT may be considered with extreme caution and close cardiology supervision. For persistent or permanent AFib, the risks generally outweigh the benefits, and TRT is often contraindicated. A thorough discussion with both your cardiologist and endocrinologist is essential.

What is the most important test before starting TRT for heart risk?

Thyroid Stimulating Hormone (TSH) test is arguably the most critical yet commonly overlooked screen. Subclinical hyperthyroidism (low TSH) is a strong, independent, and treatable risk factor for AFib. Correcting it first removes a major confounding variable. Of course, a baseline EKG and hematocrit are also mandatory.

Does the type of TRT (gel, injection, pellet) affect AFib risk?

There is no direct head-to-head trial data comparing AFib incidence across formulations. Theoretically, delivery methods that cause wide swings in testosterone levels (like large, infrequent injections) could be more provocative to heart rhythm than stable, daily transdermal applications. The TRAVERSE trial data, which showed the increased risk, came from a transdermal gel.

How does low testosterone itself affect AFib risk?

Emerging data suggests low testosterone is also a risk factor, creating the U-shaped curve. The mechanisms may involve increased inflammation, endothelial dysfunction, and worsening of other AFib risk factors like obesity and sleep apnea. This is why simply having a low T level doesn’t automatically make TRT “safe”, the goal is careful normalization, not supraphysiological elevation.

Should I stop my omega-3 supplements if I’m on TRT?

You don’t necessarily need to stop, but you should be dose-aware. If you are taking a high-dose omega-3 supplement (over 1500 mg of EPA/DHA per day) and are on TRT, especially with other heart risks, discuss this with your doctor. The combined effect may elevate risk. A lower dose (under 1000 mg/day) for general health is likely a safer choice in this context.

The Bottom Line

The link between TRT and atrial fibrillation is real, small, and mediated by a U-shaped risk curve. The difference in AF incidence (3.5% vs. 2.4%) from the TRAVERSE trial is a key finding to consider.

Your action plan is straightforward. First, rule out silent contributors, starting with your thyroid. Treat subclinical hyperthyroidism before you ever touch a testosterone bottle. Second, get a baseline electrical map of your heart with an EKG. Third, if you have existing AFib, the decision becomes a complex negotiation between symptom relief and rhythm stability, led by your cardiologist.

This is about deploying TRT intelligently on a stable foundation. Manage the variables you can control, thyroid, sleep apnea, blood pressure, hematocrit, and you turn a statistical risk into a managed, monitored part of your health protocol. Your results, tracked with diligence, are the real test.